DelveInsight pipeline reports reveal robust clinical development across three cancer indications, with 45+ companies advancing cutaneous squamous cell carcinoma therapies, 70+ companies developing liver cancer treatments, and multiple hepatocellular carcinoma candidates receiving FDA designations in 2025-2026.
Secondary analysis of KEYNOTE-716 trial finds adjuvant pembrolizumab improves recurrence-free survival in stage IIB/IIC melanoma without increasing new primary melanoma risk, while reducing non-melanoma skin cancers.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT06409195 |
A Trial to Study the Safety and Efficacy of SM-020 Gel 1.0% in Subjects With Seborrheic Keratoses and Non-Melanoma Skin Cancers |
RECRUITING | PHASE2 |
| NCT05315128 |
Intralesional Versus Intramuscular Methotrexate for Non-melanoma Skin Cancers |
COMPLETED | PHASE2 |
| NCT04160065 |
Immunotherapy With IFx-Hu2.0 Vaccine for Advanced Non-melanoma Skin Cancers |
COMPLETED | PHASE1 |
| NCT02423863 |
In Situ, Autologous Therapeutic Vaccination Against Solid Cancers With Intratumoral Hiltonol® |
COMPLETED | PHASE2 |
